Are lycopene metabolites metabolically active?

Nikki A Ford1, John W Erdman

  • 1Department of Nutritional Sciences, University of Texas, Austin, USA.

Insights

Lycopene metabolites, found in tomatoes, show potential in preventing chronic diseases like prostate cancer. These compounds may be biologically active at normal body concentrations.

Area of Science:

  • Nutritional biochemistry
  • Cancer research
  • Carotenoid metabolism

Background:

  • Lycopene, a tomato carotenoid, is linked to reduced chronic disease risk, particularly prostate cancer.
  • The hypothesis suggests lycopene metabolites, not just lycopene, are key to these health benefits.
  • These metabolites are found in serum and tissues at levels comparable to bioactive retinoids.

Purpose of the Study:

  • To review current literature on lycopene metabolites and their role in disease prevention.
  • To present new evidence supporting the bioactivity of lycopene metabolites at physiological concentrations.
  • To explore the mechanisms by which lycopene metabolites may prevent chronic diseases.

Main Methods:

  • Literature review of recent studies on lycopene metabolites.
  • Analysis of evidence regarding metabolite concentrations in biological systems.
  • Examination of reported cellular and molecular effects of lycopene metabolites.

Main Results:

  • Lycopene metabolites have been shown to inhibit cancer cell proliferation.
  • These metabolites can induce apoptosis (programmed cell death) in cancer cells.
  • Evidence suggests modulation of cell cycle, gap junction communication, and androgen signaling by lycopene metabolites.

Conclusions:

  • Lycopene metabolites may exert significant biological effects at concentrations found in the body.
  • These findings support the role of lycopene metabolites in the prevention of chronic diseases.
  • Further research into lycopene metabolite mechanisms is warranted for therapeutic applications.

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...